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Aims: Advanced therapy medicinal products (ATMPs) represent a new category of
medicinal products with a potential for transformative improvements in health out-
comes but at exceptionally high prices. Routine adoption of ATMPs requires robust
evidence of their cost-effectiveness.
Methods: A systematic literature review of economic evaluations of ATMPs, includ-
ing gene therapies, somatic cell therapies and tissue-engineered products, was con-
ducted. Literature was searched using MedLine, Embase, PubMed, Cochrane
Register, the NHS Economic Evaluation Database and the grey literature of health
technology assessment organisations with search terms relating to ATMPs and eco-
nomic evaluations. Titles were screened independently by 2 reviewers. Articles
deemed to meet the inclusion criteria were screened independently on abstract, and
full texts reviewed. Study findings were appraised critically.
Results: 4514 articles were identified, of which 23 met the inclusion criteria. There
was some evidence supporting the cost-effectiveness of: chimeric antigen receptor
T-cell therapy axicabtagene–ciloleucel (Yescarta), embryonic neural stem cells,
tumour infiltrating lymphocytes, in vitro expanded myoblast, autologous chondrocyte
implantation, ex vivo gene therapy (Strimvelis) and voretigene neparvovec (Luxturna).
However, estimates of cost-effectiveness were associated with significant uncertain-
ty and high likelihood of bias, resulting from largely unknown long-term outcomes, a
paucity of evidence on health state utilities and extensive modelling assumptions.
Conclusion: There are critical limitations to the economic evidence for ATMPs, most
notably in relation to evidence on the durability of treatment effect, and the reliabil-
ity of opinion-based assumptions necessary when evidence is absent.
K E YWORD S
cell therapy, cost-effectiveness, gene therapy, health technology assessment, regenerative
medicine
1 | INTRODUCTION
Advanced therapy medicinal products (ATMPs), which include gene
therapies, somatic cell therapies and tissue-engineered products
have the potential for transformative improvements in health
outcomes for a wide range of diseases, including certain cancers,
neurodegenerative and cardiovascular diseases.1,2 Clinical
application of somatic cell therapies and tissue-engineered products
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is frequently referred to as regenerative medicine. The number
of ATMPs being approved is rising3 and, given their high
cost, there is a pressing need for robust economic evidence
of these therapies in order to inform decisions made by
healthcare payers.
ATMPs pose specific challenges in evidence generation, health
technology assessment (HTA) and financing.4 A key feature of
ATMPs is their price, which can in some instances exceed
£1m per patient. Such high (often up-front) costs make ATMPs
particularly problematic in terms of meeting usual thresholds of
cost-effectiveness and being affordable to healthcare payers.
Moreover, there may be methodological challenges, such as in
relation to uncertainty in the evidence of the effectiveness
of newly approved ATMPs; the nature of the distribution of
costs in relation to the accrual of benefits, and how these are
affected by choice of discount rates; whether curative treatments
may be considered differently to treatments that create
smaller incremental benefits; and consideration of value attributes
that may not be captured adequately in the quality-adjusted life
year (QALY).
The National Institute for Health and Care Excellence (NICE) in
the UK suggested that a completely new reference case is not
needed. Their mock economic evaluation of a chimeric antigen
receptor (CAR) T-cell therapy accepted existing methods of eco-
nomic evaluation as being fit for purpose in the evaluation of
ATMPs.5 More recently, the independent US-based Institute for
Clinical and Economic Review following a review in collaboration
with NICE and the Canadian Agency for Drugs and Technologies in
Health, published adaptations to its value assessment framework for
potential cures and other treatments that qualify as high-impact sin-
gle or short-term therapies.6 Marsden et al. (2019)7 suggested new
analytic approaches are required, suggesting that “patients with rare
genetic diseases, along with the gene replacement therapies they
use, present a unique set of conditions that warrant equally unique
analytic approaches to estimating value for money.” Similarly, Drum-
mond et al. (2019)8 suggested that some unique characteristics need
to be taken into account.
The aim of this study was to review and critique published eco-
nomic evaluations of ATMPs, in order to: (i) highlight current evidence
on the cost-effectiveness of ATMPs; (ii) identify specific methodologi-
cal challenges; and (iii) assess how these challenges were approached
by analysts.
2 | METHODS
2.1 | Protocol, registration and reporting
The protocol for this review was registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO, reference
CRD42019125069). The review is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.9
2.2 | Review question
The principal review question was: what are the main challenges and
solutions for the economic evaluation of ATMPs?
2.3 | Search strategy
We searched the literature using MedLine, Embase, PubMed,
Cochrane Central Register of Controlled Trials, National Health Ser-
vice Economic Evaluation Database, Health Technology Assessment
Centre for Reviews and Dissemination, and Web of Science, for rele-
vant articles published from database inception up to April 2019. The
search strategy involved combining terms for ATMPs and economic
evaluations using the Boolean ‘AND’ operator. The search was
restricted to studies of human subjects and written in the English lan-
guage. An additional search of the grey literature contained within the
websites of HTA organisations was conducted. Further articles were
identified from other related systematic reviews and reference lists of
included studies. The full search strategy is detailed below.
(Strimvelis [tw] OR “Autologous chondrocyte implantation”
[tw] OR Imlygic [tw] OR Luxturna [tw] OR Yescarta [tw] OR Kymriah
[tw] OR tisagenlecleucel [tw] OR “chimeric antigen receptor” [tw] OR
CAR-T [tw]) OR Gencidine [tw] OR Oncorine [tw] OR Neovasculgen
[tw] OR Zalmoxis [tw] OR tonogenchoncel-L [tw] OR GS010 [tw] OR
NSR-REP1 [tw] OR “valoctocogene roxaparvovec” [tw] OR AMT-061
[tw] OR AVXS-101 [tw] OR Generx [tw] OR RT-100 [tw] OR Pexa-
Vec [tw] OR Collategene [tw] OR VM202 [tw] OR “LentiGlobin
BB305” [tw] OR Lenti-D [tw] OR GSK2696274 [tw]) AND (economics
[mh] OR “health technology assessment” [tw]) AND english [la].
2.4 | Eligibility criteria/study selection
Economic evaluations of ATMPs, reported in full, published in the past
20 years (2000–2019) and in the English language were included.
Only full economic evaluations were included (i.e. cost effectiveness,
cost utility or cost benefit analyses). Partial economic evaluations
(e.g. cost minimisation or cost consequence analyses) were excluded,
as were studies only reporting the burden of disease or cost of illness.
We excluded editorials, letters, historical articles, discussion or com-
mentary articles, and evaluations published only as abstracts.
2.5 | Data extraction
Identified articles were screened by 2 reviewers independently
according to the exclusion and inclusion criteria; first by title, followed
by abstract, and finally by full article text. Any discrepancies were
resolved in discussion with the third reviewer. Extracted data included
year and country of publication, clinical indication, ATMP and compar-
ator, method of economic evaluation, time horizon, total intervention
and comparator costs, QALY gain, incremental cost-effectiveness
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ratios (ICERs), results of sensitivity analyses, principal study findings,
issues of generalisability, study limitations and key methodological
challenges as reported by the authors of each study.
2.6 | Quality of reporting assessment
Articles were assessed for their quality of reporting by their compli-
ance with the Consolidated Health Economic Evaluation Reporting
Standards.10 Studies were scored against each of the 24 checklist
items according to whether reporting fully satisfied or did not satisfy
the item requirements. The overall quality of reporting was presented
as a percentage score of applicable items. Studies scoring above an
arbitrary threshold of 75% were considered to be of higher reporting
quality. The quality of reporting of individual items from the checklist
is expanded further in the narrative.
2.7 | Narrative synthesis
A narrative synthesis of the methodological challenges associated
with economic evaluations of ATMPs was carried out following the
methods of Nagpal et al. (2019),11 and based on the information
extracted and judgements made on study quality. This approach syn-
thesises findings from multiple studies and uses the words and text
from these studies to produce a summary and explanation of the find-
ings therein.
3 | RESULTS
3.1 | Search results
In total, 4514 studies were identified following the initial search.
Removal of duplicates resulted in 3358 potentially relevant articles.
Title screening resulted in 115 papers, which further reduced to 35 fol-
lowing abstract screening, and 18 following the review of full article
texts. The reasons for exclusion are given in Figure 1. Five additional
papers were identified from other sources, resulting in 23 studies
being included in the review. The data extracted from the included
studies are presented in Tables 1–3.
3.2 | Study characteristics
The review identified economic evaluations of the following
ATMPs: CAR T-cell therapies tisagenlecleucel (Kymriah) and
axicabtagene–ciloleucel (Yescarta), embryonic neural stem cells,
tumour infiltrating lymphocytes (TIL), in vitro expanded myoblast
(IVM), autologous chondrocyte implantation (ACI), autologous
CD34+ cells transduced with a lentiviral vector containing
the human adenosine deaminase gene (Strimvelis), and voretigene
neparvovec (Luxturna).
The main clinical indications included acute lymphoblastic leukae-
mia, Parkinson's disease, haemophilia, defects of the bladder, knee
cartilage lesions, adenosine deaminase deficiency, melanoma, stroke,
multiple sclerosis and retinal disease.
Of the identified papers, 16 were cost–utility
analyses5,12–19,22,23,25,27,28,30–33 and 5 were cost-effectiveness ana-
lyses.20,21,24,26,29 Most studies used some form of economic model-
ling, mainly Markov models (8 studies),12,16–19,25,30,31 but also
decision trees,17,19–25,28,29,31,32 microsimulation,14 survival model-
ling15,16 or the headroom method.26
The time horizon of included studies varied from 1 year, to life-
time in 12 studies which extrapolated costs and outcomes beyond the
available clinical evidence.
3.3 | Principal study findings
3.3.1 | Somatic-cell therapy medicines
There were 8 economic evaluations of CAR T-cell therapies, of
which 6 suggested they were cost effective. As a bridge to
haematopoietic stem cell transplantation, and adopting the rec-
ommended methods of NICE, Hettle et al. (2017)5 estimated an
ICER of £49 995 per QALY gained, which exceeds the usual NICE
threshold range for cost-effectiveness. Sarkar et al. (2019)14 found
that CAR T-cell therapy (unspecified) for relapsed/refractory B-cell
acute lymphoblastic leukaemia increased overall cost by US
$528 200 and improved outcomes by 8.18 QALYs, resulting in an
ICER of $64 600 per QALY gained from a US payer perspective.
Cost effectiveness was established in 94.8% of iterations at a will-
ingness to pay $100 000 per QALY. In Tice et al. (2018)19 the
probability of cost-effectiveness of tisagenlecleucel for childhood
B-cell acute lymphoblastic leukaemia at US$50 000 per QALY was
just over 70%. These were consistent with Whittington et al.
(2018),21 who estimated an ICER in the range of US$37 000 to
$78 000 per QALY gained. The Scottish Medicines Consortium
(SMC)15 appraised the manufacturer's submission of axicabtagene–
ciloleucel, which had an ICER of £57 943 per QALY gained and,
given its ultra-orphan status, accepted the greater uncertainty in
the economic case. Roth (2018)23 also assessed axicabtagene–
ciloleucel and found it to be a potentially cost-effective alternative
to salvage chemotherapy. The SMC's appraisal of tisagenlecleucel
(Kymriah)16 identified an ICER of £49 975 per QALY gained, and
was not considered cost-effective.
Other economic evaluations of cell-based therapies include a
cost utility analysis by Hjelmgren et al. (2006)12 who claimed that
embryonic neural stem cells were cost saving in patients with
early-onset Parkinson's disease. Retel et al. (2017)13 report that TIL
is expected to generate more QALYs than its comparator at a
lower cost and so is dominant. Intracerebral stem cell implantation
in stroke patients was found to be cost saving by Svensson et al.
(2012),17 under the assumption that stem cell therapy promotes
functional recovery in stroke, improves quality of life and reduces
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societal costs. Tappenden et al. (2010)18 found that autologous
haematopoietic stem cell transplantation had the potential to
achieve a level of cost effectiveness that is acceptable to
policymakers and health care purchasers, but is largely determined
by the interpretation of available clinical effectiveness data and the
duration over which such effects may be observed. Vilsboll et al.
(2018)20 found IVM to be dominated by midurethral sling treat-
ment (the comparator) but speculated that the cost of the IVM
procedure would reduce in the future as the costs of cell expan-
sion reduce.
3.3.2 | Tissue-engineered medicines
There were 5 economic evaluations of ACI. One was a cost-
effectiveness analysis,24 which reported that a 1-point increase in
clinical scores (patient reported outcome measures) had lower costs
for microfracture (MF) than for ACI at 5 years. Among the cost–
utility analyses, Gerlier et al. (2010)25 showed CondroCelect to be
cost-effective compared with MF with an ICER of €16 229 per
QALY gained. The main finding in Mistry et al. (2017)27 was that if
the decision-maker is willing to pay £20 000 for a QALY, ACI is
56–59% more likely to be cost-effective than MF. Samuelson et al.
(2012)28 estimated the average cost per QALY for periosteum-
covered ACI to be $9466 compared with $9243 for collagen-
covered ACI; no ICERs were presented. De Windt et al. (2018)29
compared single-stage cartilage repair (instant allogeneic mesenchy-
mal stromal [stem] cells product accompanying autologous
chondron transplantation) with microfracture, and estimated the
ICER to range from €28 588 to €147 513 per QALY gained. How-
ever, compared with ACI, the single-stage procedure was forecast
to be cost saving over a 5-year horizon, largely as the cell expan-
sion procedure is rendered redundant.
McAteer et al. (2007)26 utilised the headroom method to guide
investment decisions in regenerative medicine. Based on tissue engi-
neering applications in the urinary tract, they estimated a headroom
F IGURE 1 PRISMA flowchart for this review. ATMP, advanced therapy medicinal product
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TABLE 1 Principal characteristics of included studies
Reference Year
Country
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of around £16 268, but noted the limited market, which may reduce
potential profitability.
3.3.3 | Gene therapy medicines
The cost effectiveness of Strimvelis was examined in 2 analyses, of
which 1 was deemed to be cost effective. South et al. (2018)32
reported a NICE Highly Specialised Technology Evaluation which esti-
mated the most plausible ICERs for Strimvelis to be lower than
£100 000 per QALY gained. NICE approved Strimvelis for the treat-
ment of adenosine deaminase severe combined immunodeficiency,
where a matched related donor is unavailable.31 In the treatment of
severe haemophilia A, Machin et al. (2018)30 found that gene therapy
is likely to be cost saving compared with the current standard of care
involving FVIII prophylaxis. Zimmerman et al. (2019)33 estimated the
ICER for voretigene neparvovec (Luxturna) for the treatment for
vision loss owing to the ultra-rare RPE65-mediated inherited retinal
disorders, at $480 100 per QALY gained. This was driven largely by
the high cost of treatment and the relatively low gains in QALYs (1.3
over a lifetime), consistent with treatments that are neither curative
nor extend life expectancy.
3.4 | Quality of reporting
In terms of reporting, 13 studies13,14,18–22,25,27,29,30,33 were deemed
to be of good quality (see Supplementary Appendix S1). However,
many were incomplete with respect to important methodological
detail. The perspective was unclear in 7 of the studies.15,16,24,26,28,31,32
Two studies15,16 did not state explicitly the modelling approach. Three
studies24,27,28 did not mention explicitly a time horizon. Four stud-
ies15,16,20,29 did not specify whether costs and outcomes were
discounted. The reporting of sensitivity analysis was more complete,
with evidence of deterministic univariate sensitivity analysis and mul-
tivariate probabilistic sensitivity analysis having been conducted in the
majority of studies, with only 224,26 not mentioning any sensitivity
analysis. While reporting quality was not analysed by study attributes,
such as authorship affiliation, grey vs standard literature or country of
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model)
20 years
ATMP, advanced therapy medicinal product; CAR, chimeric antigen receptor; ACI, autologous chondrocyte implantation; MSC, allogeneic mesenchymal
stromal (stem) cells; CUA, cost-utility analysis; CBA, cost–benefit analysis; CEA, cost-effectiveness analysis
6 LLOYD-WILLIAMS AND HUGHES













5 £449 128 £75 962 8.82–1.36 = 7.46 £49 9951 If the discount rate for costs and outcomes was
reduced to 1.5% then the cost per QALY would
be reduced to £35 162.













Univariate analysis: Time horizon (10, 20, 30 years);
discount rate (0%, 5%); treatment efficacy (
±50%); occurrence of complications (±100%);
analytical perspective (direct medical costs only
vs including other direct costs); method of
determining utilities. The ICER was cost saving
for most variables with the exception of
postoperative disease progression, where it was
cost increasing
13
€62 000 €91 487 0.07 Intervention
dominates ICER
n/a
The parameters with the most impact on the
incremental costs were survival, drop-outs and
costs of treatment. For the incremental QALYs,
these were survival and utilities.
14 $968 800 $440 600 16.76–8.58 = 8.18 $64 6001 If the 1-year survival dropped below 57.8% then
the ICER rose above $100 000 per QALY, and
CAR T-cell therapy would not be considered cost
effective.
15 £1 035 601 £405 126 31.3–22.8 = 8.5 £74 4301 No sensitivity analysis performed.
16 Not reported Not reported 4.1 £57 943 The results are associated with increased
uncertainty when key variables in the model
were revised.
17 $202 901 $221 956 1.34 Intervention is cost
saving
Univariate analysis: relative efficacy of SCT; mode
of transplantation; age at stroke onset; annual
risk of recurrent stroke; SCT procedure risk of
death; intervention on mRS3/4; extended leave
period. The highest ICER came with intervention
on mRS 4.
18 £131 666 £107 126 4.1–5.12 = −1.02 Intervention is
dominated
Univariate analysis: Transplant related mortality
rate (0/1.3%); relative PFS hazard ratio between
HSCT and mitoxantrone; tariff cost of HSCT (
±25%), costs of managing multiple sclerosis (
±25%); discount rate (0/3.5%). The ICER is most
sensitive to the cost of transplantation itself.
19 $666 754 $337 256 9.28–2.10 = 7.18 $45 8711 Uncertainty around long-term survival was
explored through variation in the discount rate
used in the sensitivity analysis
20




One-way sensitivity analysis based on the upper
limit cure rate for in vitro expanded myoblasts
indicates that this may become more effective as
compared with the standard midurethral slings
procedure.
21 $667 000 $337 000 9.28 $46 0001 Across scenario analyses that included more
conservative assumptions regarding long-term
relapse and survival, the ICER ranged from
$37 000 to $78 000 per QALY gained.
22 $599 000 $374 000 12.1 $61 0001 In probabilistic sensitivity analyses, tisagenlecleucel
at a 5-year relapse-free survival rate of 40% was
cost effective in 99.3, 98.7 and 6.0% of
simulations at willingness to pay thresholds of
$150 000, $100 000 and $50 000, respectively
(Continues)













23 $552 921 $172 737 7.67–1.13 = 6.54 $55 1281 Scenario analyses in which patients in remission
had mortality rates 10
% and 20% higher than the age-matched general
US population. Cost-effectiveness was most
sensitive to the fraction achieving long-term




€14 238 €4329 Not reported €2134* A 66% reduction in the total costs following ACI or
a 190% increase in the total costs of
microfracture led to equivalent total costs at
5 years
25
€24 879 €1035 1.282 €16 2291 Probabilistic sensitivity analysis showed that 80%
of simulations were below a threshold of
€22 000 per QALY
26 Not reported Not reported Not reported £16 2682 n/a
27 £17 740 £3020 n/a £14 3951 Cost of cells for ChondroCelect were £16 000.
Sensitivity analysis was conducted to vary this
figure by reducing the costs by 25, 50 and 75%.
The time horizon was also varied by 10, 20, 30,
40 and 50 years. The cost of cells are a key
driver for the ICER.
28 $66 752 $66 939 0.07 $9466 (average
cost-effectiveness
ratio)
Sensitivity analysis was performed regarding the
additional cost of the type I/III collagen patch
($780) in ACI-C as well as the rate of graft
hypertrophy after ACI-P (25%). Small changes in
outcome affects the ICER substantially so that
ACI-P becomes more cost effective if the utility
value of patients doing well after ACI-P is
increased slightly from 0.85 to 0.86 or that of
ACI-C is decreased slightly from 0.85 to 0.84.
29
€11 797 €6081 (MF) 0.04 €610 6001 If the utilities of IMPACT were 10% lower than
ACI, the maximum costs of IMPACT would be
€23 697
Gene therapy
30 $1 022 049 $1 693 630 8.33–6.62 = 1.71 Intervention
dominates ICER
n/a
Only variation of gene therapy cost caused the
gene therapy strategy to be no longer cost
saving compared with prophylaxis
31 Not reported Not reported 13.6 £36 3601 NICE evidence review group proposed a list of
changes to be included as a sensitivity analysis.
These increased the ICER from the company
base case to £86 815 per QALY gained.
32 Not reported Not reported n/a £49 9751 The results are associated with increased
uncertainty when key variables in the model
were revised.
33 $1 039 000 $213 400 1.3 $480 1001 For different levels of visual ability, the ICER and
the necessary discount to reach a defined
willingness to pay threshold was calculated. The
ICER decreased with increasing visual ability at
baseline.
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; HY, Hoehn and Yahr (scale); CAR, chimeric antigen receptor; SCT, stem cell
transplant; mRS, modified Rankin scale; PFS, progression-free survival; HSCT, haematopoietic stem cell transplantation; ACI, autologous chondrocyte
implantation; ACI-C, collagen-covered ACI; ACI-P, periosteum-covered ACI; IMPACT, instant allogeneic mesenchymal stromal cells product accompanying
autologous chondron transplantation
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TABLE 3 Principal findings, issues of generalisability, limitations and methodological challenges of included studies as reported by study
authors




5 Main purpose was to report
the potential
cost-effectiveness of CAR
T-cell therapy; and to
highlight key uncertainties
surrounding these results.
Not reported. This exercise was conducted
on theoretical data and














of this uncertainty are
sufficient. Challenges
include: the potential
curative nature and claims
of long-term/lifetime
benefits; the potentially







issues; and the potentially
significant upfront costs
that may arise.
12 Long-term cost savings in
most instances in early
onset Parkinson's disease
patients in HY stages III-IV.
The model was based on the
Swedish health care system,
but devised to be applicable
to available data on
treatment costs and health
state utilities for different
HY stages. Such data are
now available from a variety
of countries.
Small number of patient-level
data; clinical effectiveness
data based on open-label
transplantation trials
The frequent use of placebo
as a comparator, together
with the extra attention
given to randomised
control trial patients may
contribute to
nonrepresentative
outcomes. Use of real-life
observations claimed to
be less restricting to allow
hypothetical comparisons
between standard




to generate more QALYs
than its comparator at a
lower cost and so
dominates.
The prices of treatments vary
substantially between
countries. This reduces the
generalisability of the
results.
No clinical trial data available
and therefore data on the
effectiveness of tumour
infiltrating lymphocytes had
to be drawn from various
sources.
It is unknown which patient
subgroup had the best
response to tumour
infiltrating lymphocytes.
14 CAR T-cell therapy increased
overall cost by $528 200
and improved effectiveness
by 8.18 QALYs, which
produced an ICER of
$64 600 per QALY per
payer perspective. Cost
effectiveness was
established in 94.8% of
iterations at a willingness to
pay of $100 000 per QALY.
Not reported. CAR T-cell therapy is a new
therapy and thus long-term
data on survival, costs, role




results are lacking. Model
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TABLE 3 (Continued)
Reference Study findings Generalisability Limitations
Key methodological
difficulties




greater uncertainty in the
economic case, despite a
base case ICER of £57 943
per QALY gained.





ciloleucel is a curative
treatment.
16 The intervention produced an
ICER of £49 975 per QALY
gained when compared to
chemotherapy regimen
gen-ox, which is under the
NICE £50 000 threshold
Not reported. Haematological malignancy
research network data were
used to estimate overall
survival for chemotherapy
patients meaning that a
naïve indirect comparison
was used as the basis of the
estimation of clinical
outcomes in the economic
model.
An assumption was made
that that patients who
were alive at 24 months
were effectively cured.
17 A potential for long-term cost
savings by reducing the
disability after stroke;
societal value up to US
$166 500 (US $184 567),
particularly in younger
patients with stroke with
moderate disability, with
possible cost effectiveness
estimated down to relative
efficacy of 14%.
Enables cost–benefit analysis
for patients with stroke
under a wide range of
assumptions
Effectiveness of SCT was
based on expert opinion;
did not include differential
costs of early vs late
administration poststroke;






analyses are based on
long-term data. If not




modelling provides a way
of estimating long term
effects.
18 A potential to achieve a level
of cost effectiveness that is
acceptable to policymakers
and health care purchasers,
but is largely determined by
the interpretation of
available clinical
effectiveness data and the
duration over which such
effects may be observed.
The focus of the analysis was
on the potential cost
effectiveness of autologous
HSCT in the management
of secondary progressive
multiple sclerosis only.
The absence of direct
randomised controlled trial




for good quality clinical
trial evidence.
19 Total cost for tisagenlecleucel
was double that of
clofarabine, while the gains
in QALYs of tisagenlecleucel
was 4× that of clofarabine.
The probability of
cost-effectiveness at
$50 000 per QALY was
about 0.7.
Cost perspective specific to
US payer which may not be
generalisable to other
settings.
This analysis was limited







being made related to trial
survival curve extrapolation






methodology used in the
‘curative intent’ mock
evaluation of CAR T-cell
therapy.5 The differences
in estimates between the
2 models are probably
due to the use of 2
different approaches to
curve extrapolation.
20 IVM is dominated by MUS
treatment but as costs of
cell expansion are likely to
reduce in the future this
may reduce the cost of the
IVM procedure.





Lack of uniform reporting
tools to define outcome of
stress urinary incontinence
interventions. When robust




outcomes measures in the
context of urinary
incontinence.
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TABLE 3 (Continued)
Reference Study findings Generalisability Limitations
Key methodological
difficulties
the estimates relied on
expert opinions.
21 The cost-effectiveness is
probably between $37 000
and $78 000 per QALY
gained over a patient's
lifetime horizon.
Not reported. Lack of evidence for the
comparator, which affects
the calculation of the ICER.
Due to limited follow up,
assumptions had to be
made about long-term
survival and when a patient
is effectively cured.








in the tail exists;
therefore, they used a
flexible parametric model
to account for this
flattening.
22 Reduction of the price of
tisagenlecleucel to
$200 000 or $350 000
would allow it to meet a
$100 000 or $150 000 per
QALY willingness-to-pay
threshold in all scenarios.
Not reported No high-quality long-term
clinical outcomes data exist
for tisagenlecleucel








23 The likelihood that
axicabtagene–ciloleucel is
cost-effective was 95% at a
willingness to pay of
$100 000 per QALY.
Not reported The current data of the
ZUMA-1 trial are limited at
a median follow up of
15.4 months.
As this analysis used
axicabtagene–ciloleucel
1-year follow-up data, the





24 For all measures, a 1-point
increase in clinical scores
had lower costs for
microfracture than for ACI
at 5 years.





Small study population leading
to bias. MF group had
slightly smaller lesions






25 ChondroCelect shown to be a
cost-effective strategy
compared with
microfracture and the ICER
is below the NICE
threshold.
Not reported. Absence of firm data on the
probability and time to
occurrence of osteoarthritis
TKR. Therefore, a Markov
model was not possible.
When the need for TKR
increases, ICER expected
to decrease in favour of
ChondroCelect. Due to
higher discount rates for
costs rather than effects,
the procedure resulting in
more TKR patients would
also generate more
QALYs. However, for the
patient the optimal
treatment is 1 that
minimises pain and
discomfort and avoids the
need for TKR. Long-term
data are needed to
characterise specific
events.
26 The headroom for
tissue-engineered bladder
was estimated at around
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TABLE 3 (Continued)
Reference Study findings Generalisability Limitations
Key methodological
difficulties
£16 268. However, the





have very wide parameter
uncertainty. In the case of
a technology yet to be
developed, or in early
stages of development,
the very nature of the
product is uncertain,
leading to difficulties in its
economic evaluation;
although the method
proposed is a simple cost
utility analysis.
27 If the decision-maker is willing
to pay £20 000 for a QALY,
ACI is 56–59% more likely
to be cost-effective than
microfracture.
Not reported. The length of clinical trial
follow-up was too short and
hence, there are no
long-term data on the
success and failure rates.
Because of the paucity of
data from clinical studies,
transition probabilities were
not available for each
transition in the model.
There is a clear lack of
evidence on health state
utility values for patients
that have had cartilage
defects of the knee.
29 IMPACT can be dominant to
ACI over a 5-year horizon in
terms of cost effectiveness
All costs were derived from
the hospital administration
data and/or from other
Dutch data resources,
which may limit its
transferability to other
settings.
Patients included in these
models, who reflect
randomised controlled trial
populations, are not always
typical of patients seen in
orthopaedic sports practice.
Included only a small
number of patients from a
randomised controlled
trial with a follow-up of
5 years. Greater patient
numbers and a longer
follow-up period will
make such an early
analysis more reliable.
Gene therapy
27 Treatment with gene therapy
is likely to be cost saving for
the treatment of severe
haemophilia A compared
with the current standard of
care with factor VIII
prophylaxis.
Age is an important variable in
potentially curative
treatments. The results are
generalisable to different
age groups because altering
the probability of death, a
good approximation for






results in full quality of life
could potentially bias results
toward gene therapy. The
lack of commercially
available gene therapy for
haemophilia A. limiting the




The assumption that gene
therapy leads to full
quality of life could
potentially bias the results
towards gene therapy.
13 The ICER for Strimvelis is




Not reported. Quality of life data had to be
collected from the
literature.
Discount rate was 1.5% per
annum as the treatment
comes under the
definition NICE uses for a
treatment that restores
people to full or near-full
health when they would
otherwise die.
17 The most plausible ICERs
were lower than £100 000
per QALY gained and that
Strimvelis should be
recommended for treatment
Not reported. Given the rarity of the disease,
there were some issues
with the representativeness
of the population that had
received Strimvelis to the




controlled trials in much
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one reporting organisation. Variability in the quality of reporting of
manufacturers' submissions to health technology agencies, as
one example, is likely to be a function of what can be disclosed pub-
licly, the level of detail provided by the manufacturer as well as the
reporting template used. It is important to recognise that reporting
quality may not reflect methodological quality.
3.5 | Methodological challenges
3.5.1 | Size and design of trials
A recurring theme in the literature relates to the small size of clini-
cal trials and the methodological challenges this presents. All
ATMPs to date are indicated for rare diseases, which presents a
challenge in terms of patient recruitment but, nonetheless, trials
risk being statistically underpowered. Aae et al. (2018)24 highlighted
the small sample sizes in trials, which might increase the risk
of false negative findings, but perhaps equally important, also
reduces the precision of the estimate of treatment effectiveness.
Further evidence, including from post-approval studies (e.g. Lam
et al. 2019)34 are necessary to reduce uncertainty in key clinical
parameters.
3.5.2 | Lack of data on disease progression and
long-term effects
Sarkar et al. (2019)14 discussed how CAR T-cell therapy is a new
therapy and so long-term data on survival, costs, the role of HSCT
after CAR T-cell therapy and complications that could affect the
cost effectiveness analysis results are lacking. Mistry et al. (2107)27
noted that the length of follow-up in the published trials of
chondral defect in the knee was too short and hence there are no
long-term data on success and failure rates. Further, because of
the paucity of data from clinical studies, transition probabilities may
not be calculable for parameterising economic models.
3.5.3 | Assumptions about efficacy and
comparative effectiveness
Many economic evaluations required strong assumptions about the
efficacy and comparative effectiveness of the ATMP, mainly due to
the limitations of the available clinical evidence. In Machin et al.
(2018),30 for instance, the assumption that successful gene therapy
results in full quality of life was not substantiated by evidence, and
could introduce significant bias in their estimates of cost-effective-
ness. Lin et al. (2018)22 stated, as a limitation, that no high-quality
long-term clinical outcomes data existed for tisagenlecleucel. Some
evaluations pertained to early phases of drug development, or were
analyses of hypothetical drugs with very limited (if any) evidence
on treatment effect. No randomised controlled trial data were
available to Retel et al. (2017),13 for instance, and therefore data
on the effectiveness of TIL had to be drawn from alternative, lower
quality evidence.35,36 A lack of comparative evidence limited the
economic evaluation of Tice et al. (2018)19 and, as evidence on
long-term survival was largely unknown, further assumptions had
to be made in relation extrapolating beyond the available evidence.
The main limitation in Gerlier et al. (2010)25 was that a Markov
TABLE 3 (Continued)
Reference Study findings Generalisability Limitations
Key methodological
difficulties
of ADA-SCID where a











33 The high ICER is driven by the
high cost of voretigene
neparvovec and the
relatively low gains in
QALYs. Voretigene
neparvovec does not
improve survival and is not
curativewk. QALY gains
come from quality of life
improvements.
Not reported. Used utility values from other
retinal disease population as
quality of life data for
RPE65-mediated retinal
disease does not exist. This
may have led to biased
outcomes.
Without long-term data, it
cannot be known how
long benefit will be
maintained.
CAR, chimeric antigen receptor; ATMP, advanced therapy medicinal product; HSCT, haematopoietic stem cell transplantation; SCT, stem cell transplant;
IVM, in vitro expanded myoblasts; MUS, midurethral slings; ACI, autologous chondrocyte implantation; TKR, total knee replacement; IMPACT, instant allo-
geneic mesenchymal stromal cells product accompanying autologous chondron transplantation; ADA-SCID, adenosine deaminase severe combined immu-
nodeficiency; HY, Hoehn and Yahr (scale); mRS, modified Rankin scale; NHS, National Health Service; QALY, quality-adjusted life year; ICER, incremental
cost-effectiveness ratio
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model could not be constructed due to there being no robust data
on the probability and time to occurrence of clinical events associ-
ated with osteoarthritis and total knee replacement. The absence
of data was the main limitation also in Tappenden et al. (2010),18
where there was no randomised controlled trial evidence to input
into the model; and Vilsboll et al. (2018)20 who reported a lack of
uniform reporting tools to define the outcome of stress urinary
incontinence interventions. Where strong evidence was not avail-
able, authors often relied on expert opinion. In the NICE (2016)31
review of whether their current methods of economic evaluation
are fit for purpose in assessing ATMPs, they used hypothetical
datasets to assess CAR T-cell therapy in terms of a bridge to stem
cell transplantation and with curative intent. They used theoretical
prices that would result in the therapies being valued at the NICE
willingness to pay thresholds of cost-effectiveness. Overall, they
found that while current NICE methods and processes were indeed
robust and relevant for the appraisal of ATMPs, quantification of
clinical outcomes and uncertainty were key to their evaluation.
3.5.4 | Lack of data on health-related quality of
life/utilities
The NICE (2017)27 assessment highlighted the limitation of relying on
external data on patient quality of life. Similarly, Samuelson et al.
(2012)28 noted a lack of available evidence and resorted to obtaining
data on health state utility, as well as outcome scores, graft hypertro-
phy and failure rates from the literature. Mistry et al. (2017)27 also
report a lack of evidence on utility values that could introduce addi-
tional uncertainty and potential bias. An absence of reliable data on
utilities undermines the robustness of QALY calculations.
3.5.5 | Generalisability
The main themes in terms of generalisability relate to costs. Costs of
ATMPs obtained from specific hospitals in specific countries, for
instance, might limit generalisability to other jurisdictions.12,13,24,28,29
This may be due to different methods of production, pricing and ser-
vice delivery in different settings. Other issues of generalisability
highlighted in the reviewed studies, include the transferability of
results from a US to a UK setting,19 the importance of age as a
variable in potentially curative treatments30 and using QALYs based
on the same multi-attribute health status classification system
internationally.20
3.6 | Analysts' resolution of methodological
challenges
The main methodological challenge was the lack of clinical data with
which to inform any modelling or economic evaluation
attempted.12,14,18,20,22,24,25,27,28 In all these studies, the problem was
addressed by recourse to the published literature, or by making
assumptions. For example, Mistry et al. (2017)27 derived transition
probabilities from 2 studies, which compared matrix-applied chondro-
cyte implantation with MF, and expert clinical opinion. Tice et al.
(2018)19 estimated the time at which long-term survivors would be
considered effectively cured based on assumptions that were neces-
sary to extrapolate the survival curve for trial participants. While dis-
ease modelling provides a way of estimating long-term effects, this
does not substitute for good quality clinical trial evidence.
4 | DISCUSSION
4.1 | Statement of principal findings
Of the 23 studies identified, 412,13,17,30 had interventions that domi-
nated the comparator (more effective, and cost-saving), while 218,20
estimated ICERs, which indicated that the interventions were domi-
nated by the comparator treatment. The remaining studies had ICERs
ranging from £14 395 per QALY gained (for autologous chondrocyte
implantation) in Mistry et al. (2017),27 to USD$610 600 per QALY
gained for instant allogeneic mesenchymal stromal cells product
accompanying.29 The narrative overview of the methodological chal-
lenges encountered in the identified papers revealed as the principal
difficulties, the paucity of trial data to inform economic analysis, the
lack of long-term data on outcomes and costs, and dependence on
critical and often unsubstantiated assumptions. The clinical evidence
was insufficient in many (if not most) instances to support claims that
treatment was curative, which has a major bearing on estimates of
survival and quality-adjusted life expectancy required for calculating
cost-effectiveness.
4.2 | Strengths and weaknesses of this review
study
The main strength of this review is that it brings together an array of
literature concerning the economic evaluation of ATMPs and
identifies, from the studies, the main methodological challenges. The
search terms were designed to have the maximum likelihood of
identifying relevant articles; however, there are likely to be
many unpublished economic evaluations submitted to HTA
organisations, and presented at conferences (although abstracts were
excluded explicitly), which were not included in the review. Our lan-
guage restriction is a further limitation that excluded economic
analyses published (or available from HTA organisations) in languages
other than English.
4.3 | Unique features of ATMPs for HTA
Although current methods of economic evaluation are considered by
some organisations to be sufficient for analysing ATMPs,5,31 there
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may be some unique features of ATMPs that require consideration
when performing such analyses. Hettle et al. (2017),5 for instance,
claim the factors that make ATMPs unique as the following: the
potentially curative nature of the therapies along with lifetime bene-
fits; the changing nature of the product characteristics over time;
potential long-term safety issues; organisational and scaling issues;
and the significant up-front cost that face payers.
Whether indeed these are unique to ATMPs is debatable
(many surgical interventions have high up-front costs with lasting
benefits; antimicrobial treatments are curative; several medicines
have potential long-term safety concerns etc.). However, their
exceptionally high costs demand higher evidential standards for
claims of survival benefits and cure. The issue of whether or not
certain ATMPs are curative is still not borne out in the literature.
For tisagenlecleucel, the SMC (2019)16 assumed it to be curative if
individuals in the study survived past 24 months. None of the eco-
nomic evaluations included a value of information analysis to quan-
tify the potential value of longer and larger trials to support the
evidence base.
The differential timing in the costs and accrual of benefits associ-
ated with ATMPs suggests that time preference, and the choice of
discount rate, is likely to be more impactful on their cost-effectiveness
compared to many other conventional health technologies. NICE
(2017)31 applied a discount rate of 1.5% per annum for costs and ben-
efits, in accordance with its guidance for treatments that restore peo-
ple to full or near-full health when they would otherwise die.37 Gerlier
et al. (2010)25 highlighted a particular problem in their evaluation of
the ATMP, ChondroCelect. Their application of a higher discount rate
for costs than for effects meant that when the need for total knee
replacement among patients with osteoarthritis receiving
ChondroCelect increased, the ICER reduced in favour of
ChondroCelect. However, the best treatment for the patient is the
1 that minimises pain and discomfort and avoids the need for knee
replacement in the first place. This type of paradox could be encoun-
tered in other contexts and should be taken into consideration when
conducting economic evaluations of ATMPs.
5 | CONCLUSION
This systematic review is a comprehensive account and methodologi-
cal critique of economic evaluations of ATMPs. In particular, it pro-
vides a narrative synthesis of the challenges facing health technology
analysts and economists in the evaluation of ATMPs. The main issue
identified was the paucity of long-term clinical trial data to inform cost
effectiveness analyses. This was the case in 11 of the 23 papers iden-
tified. Analysts had to resort to strong assumptions about the curative
nature of ATMPs and their ability to return patients to full health-
related quality of life. Such assumptions can lead to biased estimates
of cost-effectiveness and inefficient allocation of resources. There are
also implications for the funding of ATMPs, especially in terms of
outcomes-based payment, which depends critically on the measure-
ment of treatment success.
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